All News
Review of Calcium Pyrophosphate Deposition Disease
Lancet Rheumatology has published a review of Calcium pyrophosphate deposition (CPPD) disease - a chronic inflammatory and degenerative crystal arthropathy that increases with aging.
Read Article
NSAIDs Used Despite Contraindications
d
EurekAlert!
Osteoarthritis affects 600 million people worldwide, making it a leading cause of disability.
Read Article
Pain Reduction with Methotrexate in Knee Osteoarthritis
The Annals of Internal Medicine reports that oral, low dose, weekly methotrexate significantly reduced knee osteoarthritis (KOA) pain, stiffness, and function in a randomized controlled trial.
Read Article
Arthritis drugs may relieve long COVID lung symptoms
d
EurekAlert!
University of Virginia School of Medicine researchers have identified a potential treatment for the respiratory symptoms of long COVID after discovering an unknown cause of the condition inside the lungs.
Read Article
RA Inflammation and Cognitive Impairments
d
EurekAlerts!
The inflammatory activity in the body caused by rheumatoid arthritis is linked to specific cognitive impairments, finds a small comparative study, published in the open access journal RMD Open.
Read Article
New Classification Criteria for Juvenile Axial Spondyloarthritis
An expert panel has published new and validated classification criteria for axial disease in children with juvenile spondyloarthritis (SpA; AxJSpA).
Literature review - Glucocorticoid use in elderly to be problematic. GC use may be assoc w/ remission, but GC increases AE rates, & there is difficulty w/ GC discontinuation. Goal: D/C GC early, but some may require for up to yrs to control Dz activity https://t.co/6liN0mubIv https://t.co/PiGKGSYrof
Dr. John Cush RheumNow ( View Tweet)
New Classification Criteria for Juvenile Axial Spondyloarthritis
An expert panel has published new and validated classification criteria for axial disease in children with juvenile spondyloarthritis (SpA; AxJSpA).
https://t.co/kxtHlEk5XG https://t.co/jKAp9W5Di1
Dr. John Cush RheumNow ( View Tweet)
In the UK, estimated cost of hardardous NSAID use is £31.43million (pounds) (£9.28m to £67.11m) over 10 yrs. High risk = Elderly >65y without gastroprotection, pts on anticoagulants; & Pts w/ heart failure, chronic kidney Dz , or Hx of peptic ulcer. https://t.co/bPXnQbQnNV https://t.co/aDLGHjLmhB
Dr. John Cush RheumNow ( View Tweet)
Harris poll of 1286 #PsA pts (52% female) shows gender differences in perception. Women had different presenting Sxs, more joint tenderness, skin PSO, and enthesitis, and greater impact on well-being. Treating female PsA is different! https://t.co/H3PQkKCg9n https://t.co/FmwhgkVJ7J
Dr. John Cush RheumNow ( View Tweet)
Polypharmacy Doubled in 20 Years. Polypharmacy (5+ Rx last month) went from 24% in 2000 to > 40% in 2020 https://t.co/2czI4DxlVm https://t.co/VAZkbxKrJP
Dr. John Cush RheumNow ( View Tweet)
FIRST registry of 1424 #RA pts found 732 achieving HAQ-DI <0.5 & 454 w/ pain VAS <4/10. Achieiing LDA in 1st 6mos predicted by seropositivity & JAKi use. Less likely were: older, failin ≥ 2 b/tsDMARDs, hi baseline HAQ& steroid use (not comorbidities) https://t.co/7y0uMV414j https://t.co/6aLPTzf5fm
Dr. John Cush RheumNow ( View Tweet)
Location, Location, Location (7.26.2024)
Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow. Location matters; Geo-rheumatology?
https://t.co/I81qpckOQG https://t.co/cyu64ThPkN
Dr. John Cush RheumNow ( View Tweet)
Lg prospective (2013-2020) multinational, cohort of 3449 #SLE pts (F/U 2.8 yrs)- LLDAS (lupus low Dz activity achieved >= once in 73%. Sustained LLDAS >3mos assoc w/ signif less damage (HR 0·60), remission: (0·66) & flare (0·56). https://t.co/AFyOBWcIZf https://t.co/bHjmOuH7wN
Dr. John Cush RheumNow ( View Tweet)
Enhance your clinical practice with insights from the EULAR 2024 Poster Hall Presentations, now on RheumNow. This year's conference showcases pivotal research in rheumatology. Visit https://t.co/PLnIOe9vuF to stay at the forefront of medical innovation. https://t.co/vXR12HprAp
Links:
Dr. John Cush RheumNow ( View Tweet)
Biologics Prevent AA amyloidosis progression to ESRD
The study suggests that biologic drugs can prevent serious complications of rheumatologic and autoimmune diseases, with some products showing greater effectiveness than others.
https://t.co/dq5NRrsExv https://t.co/8h1g7LHdCU
Dr. John Cush RheumNow ( View Tweet)
Earlier RA Diagnosis Leads to Lower Costs of Care
A study from the Leiden Early Arthritis Clinic shows that is RA is diagnosed within 12 weeks after symptom onset, treatment costs were lower in both autoantibody-negative and autoantibody-positive RA.
https://t.co/0vI4EWfBfA https://t.co/E5q3LpxC24
Dr. John Cush RheumNow ( View Tweet)
Whats it like to be a Rheum? AMA shadows 11 yr rheumatologist Dr. Amish Dave - typical day, challenging aspects, burnout, lifestyle, skills, insights and med student advice - Thanks Dr. Dave!! https://t.co/AIfWwb4HpG https://t.co/EvFVAeqWfK
Dr. John Cush RheumNow ( View Tweet)
3 yr German laboratory study of 71,597 laboratory tests, found 238 positive tests for 13 myositis autoAbs in 209 patients. Pos. results due to Idiopathic inflammatory myopathy in 37(18%), other inflammatory rheum Dz 90 (43%) or NO Rheum Dx 82 (39%) https://t.co/1cQ4LmPEhL https://t.co/1UjuIMdF0M
Dr. John Cush RheumNow ( View Tweet)
JAK Inhibitors Reduce Macular Degeneration
Insurance claims data showed that patients with autoimmune disorders who took JAK inhibitors had lower rates of AMD, hinting that the drugs might treat the common eye disease.
https://t.co/MuJpbGPqe8 https://t.co/hcp4W3wP8a
Dr. John Cush RheumNow ( View Tweet)